Isavuconazonium Sulfate, also known as Isavuconazole, is a broad-spectrum antifungal drug used in the treatment of invasive fungal infections. It belongs to the triazole class of drugs and is available in the form of a sulfated prodrug. It is approved by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazonium Sulfate is a prodrug that converts to the active form Isavuconazole after administration. The drug works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, ultimately leading to cell death.The drug is administered intravenously and is available as a lyophilized powder for reconstitution in water for injection. The recommended dosage is 372 mg of Isavuconazonium Sulfate administered as an intravenous infusion every 8 hours for the first two days, followed by 372 mg once daily.
The most common adverse reactions reported with the use of Isavuconazonium Sulfate include nausea, vomiting, diarrhea, headache, and elevated liver enzymes. Rare but serious adverse reactions may include severe allergic reactions and hepatotoxicity. It is important to monitor patients regularly for adverse reactions while using this drug.
Isavuconazonium Sulfate is metabolized by the liver, and its dosage may need to be adjusted in patients with hepatic impairment. It has not been studied in pregnant or breastfeeding women; hence the use of this drug in such patients should be carefully considered.
Overall, Isavuconazonium Sulfate is an effective antifungal drug for the treatment of invasive aspergillosis and invasive mucormycosis. Its broad-spectrum activity makes it a promising drug for the management of a wide range of invasive fungal infections. However, it is important to use this drug judiciously, given the risk of adverse reactions associated with its use.
